Developing Therapies in Oncology & Skin Health
MedC Biopharma Corporation is a clinical-stage biopharmaceutical company focused on developing and commercializing novel class therapeutics.
Three (3) years of developing skin oncology and skin health treatments in high value market products. Currently, two drugs developed towards clinical trials: CTCL Sezary Syndrome – Skin T-cell Lymphoma, orphan condition with high mortality and unmet needs, and CTCL MF. The total estimated market for CTCL is $2 Billion market by 2025 (Diligent MR, 2017).
MedC has also developed a treatment for Cutaneous Leishmaniasis, an orphan condition with unmet needs. Leishmaniasis will have $300 Million annual market by 2027 (Fior Markets, 2020).
OTCs & Skin Health
Developing science-based and data driven natural therapeutics for the treatment of skin health and wellness conditions. Our proprietary "ALGEL" red sea-algae gel extract combined with botanical actives enables us to offer evidence based, safe to use, consumer products with substantiated claims.
Veterinary Pipeline Opportunity in pet health including Leishmaniasis , Oncology and inflammation related indications with lifesaving unmet needs